StockMacro
Menu

Insmed

$141.33 +30% in 6 monthsMarket cap $31.0B

INSM on XNAS, Health Care, Insmed, Inc., job postings

Measures activity, not value. Not investment advice.

Latest quarter revenue up 268% to $524.4M, but the 12-month net loss is $605.6M.

  • GoodShares up 50% in one month, but down 29% over 12 months
  • BadNegative free cash flow of $627.6M over 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Industry
Pharmaceutical preparations (Health Care)
Employees
1,664
Website
insmed.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $524.4M, net loss $100.3M.
Quarter to 31 Dec 2021: revenue $56.1M, net income -$113.0MQuarter to 31 Dec 2021: revenue $56.1M, net income -$113.0MQuarter to 31 Mar 2022: revenue $53.1M, net income -$94.6MQuarter to 31 Mar 2022: revenue $53.1M, net income -$94.6MQuarter to 30 Jun 2022: revenue $65.2M, net income -$95.6MQuarter to 30 Jun 2022: revenue $65.2M, net income -$95.6MQuarter to 30 Sep 2022: revenue $67.7M, net income -$131.1MQuarter to 30 Sep 2022: revenue $67.7M, net income -$131.1MQuarter to 31 Dec 2022: revenue $59.3M, net income -$160.1MQuarter to 31 Dec 2022: revenue $59.3M, net income -$160.1MQuarter to 31 Mar 2023: revenue $65.2M, net income -$159.8MQuarter to 31 Mar 2023: revenue $65.2M, net income -$159.8MQuarter to 30 Jun 2023: revenue $77.2M, net income -$244.8MQuarter to 30 Jun 2023: revenue $77.2M, net income -$244.8MQuarter to 30 Sep 2023: revenue $79.1M, net income -$158.9MQuarter to 30 Sep 2023: revenue $79.1M, net income -$158.9MQuarter to 31 Dec 2023: revenue $83.7M, net income -$186.1MQuarter to 31 Dec 2023: revenue $83.7M, net income -$186.1MQuarter to 31 Mar 2024: revenue $75.5M, net income -$157.1MQuarter to 31 Mar 2024: revenue $75.5M, net income -$157.1MQuarter to 30 Jun 2024: revenue $90.3M, net income -$300.6MQuarter to 30 Jun 2024: revenue $90.3M, net income -$300.6MQuarter to 30 Sep 2024: revenue $93.4M, net income -$220.5MQuarter to 30 Sep 2024: revenue $93.4M, net income -$220.5MQuarter to 31 Dec 2024: revenue $104.4M, net income -$235.5MQuarter to 31 Dec 2024: revenue $104.4M, net income -$235.5MQuarter to 31 Mar 2025: revenue $92.8M, net income -$256.6MQuarter to 31 Mar 2025: revenue $92.8M, net income -$256.6MQuarter to 30 Jun 2025: revenue $107.4M, net income -$321.7MQuarter to 30 Jun 2025: revenue $107.4M, net income -$321.7MQuarter to 30 Sep 2025: revenue $142.3M, net income -$370.0MQuarter to 30 Sep 2025: revenue $142.3M, net income -$370.0MQuarter to 31 Dec 2025: revenue $263.8M, net income -$328.5MQuarter to 31 Dec 2025: revenue $263.8M, net income -$328.5MQuarter to 31 Mar 2026: revenue $306.0M, net income -$163.6MQuarter to 31 Mar 2026: revenue $306.0M, net income -$163.6MQuarter to 30 Jun 2026: revenue $425.5M, net income -$13.2MQuarter to 30 Jun 2026: revenue $425.5M, net income -$13.2MQuarter to 30 Sep 2026: revenue $524.4M, net income -$100.3MQuarter to 30 Sep 2026: revenue $524.4M, net income -$100.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $524.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$524.4M-$100.3M
30 Jun 2026$425.5M-$13.2M
31 Mar 2026$306.0M-$163.6M
31 Dec 2025$263.8M-$328.5M
30 Sep 2025$142.3M-$370.0M
30 Jun 2025$107.4M-$321.7M
31 Mar 2025$92.8M-$256.6M
31 Dec 2024$104.4M-$235.5M
30 Sep 2024$93.4M-$220.5M
30 Jun 2024$90.3M-$300.6M
31 Mar 2024$75.5M-$157.1M
31 Dec 2023$83.7M-$186.1M
30 Sep 2023$79.1M-$158.9M
30 Jun 2023$77.2M-$244.8M
31 Mar 2023$65.2M-$159.8M
31 Dec 2022$59.3M-$160.1M
30 Sep 2022$67.7M-$131.1M
30 Jun 2022$65.2M-$95.6M
31 Mar 2022$53.1M-$94.6M
31 Dec 2021$56.1M-$113.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.5B $447.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +240% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$605.6M -$1.2B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.81 -$6.17
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 84.4% 76.5% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -37.1% -259% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -39.9% -265% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -72.5% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$627.6M -$906.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.1B $1.7B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $555.1M $546.8M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$591.5M (net cash) -$1.1B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.76 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.31
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 20.4 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 20.0 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 42.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
InsmedINSM (this company) $31.0Bloss20.4+240%-39.9%
Royalty PharmaRPRX $30.5B45.411.6+11%25.7%
ZoetisZTS $32.1B12.93.4+1.0%26.1%
Roivant SciencesROIV $28.0Bloss682–-838%
United TherapeuticsUTHR $23.6B19.27.4+1.9%38.6%
ViatrisVTRS $22.5Bloss1.5+4.3%-4.1%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$17.8M

bought $0, sold $17.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.6%

695 13F filers vs 652

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

100%

219.0M shares held by 13F filers (30 Sep 2026) of 219.4M outstanding (23 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.4%

14.1M shares sold short (30 Oct 2026) of 219.4M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.6

14.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.5%

13.5M shares sold short in the report before, 14.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

45%

45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-45%

11 vs 20 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+268%

$524.4M vs $142.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+133%

$5.6M vs $2.4M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$110K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

69

69 articles in the last 7 days; its usual week has 7 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.9×

69 articles in the last 7 days; its usual week has 7.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $524.4M, 3.7× a year earlier

Price $141.33 on 20 Nov 2026, -29% over 12 months (12-month range $91.88 to $211.41)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $147.4M in the last 12 months (the 12 months before: -$211.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 11 published in the last 12 months, -45% on the 12 months before.
Revenue per quarter. Revenue $524.4M in the latest quarter, +268% on a year earlier.
Capital spending per quarter. Capital spending $5.6M in the latest quarter, +133% on a year earlier.
Institutional holders (13F filers). 695 13F filers reported holding it in the latest 13F quarter, +30% on a year earlier.
Federal obligations. Federal obligations: $31K published in the last 12 months (none in the 12 months before).
Lobbying spend. Lobbying spend: $110K published in the last 12 months, +450% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
3 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 524.4M vs usual 124.9M (2026-09-30); 3.7x the same period a year earlier
20 Oct 20268-K and other filingsDirector or officer change
5 Oct 20268-K and other filingsDirector or officer change
5 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 425.5M vs usual 105.9M (2026-06-30); 4.0x the same period a year earlier
20 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: TRD (2026-06-30)
17 Jul 2026Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
16 Jun 2026Sharp changeShort interest spike: short interest spike, 19.1M vs usual 10.7M (2026-05-29); 1.1x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 17.6M vs usual 10.7M (2026-05-15); 1.1x the same period a year earlier
12 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 306.0M vs usual 98.9M (2026-03-31); 3.3x the same period a year earlier
24 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 16.6M vs usual 4.2M (2025-12-31); 2.4x the same period a year earlier
24 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 263.8M vs usual 93.1M (2025-12-31); 2.5x the same period a year earlier
19 Feb 20268-K and other filingsDirector or officer change
19 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 160 vs usual 56.50 (2025-12-31); 3.5x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 117 vs usual 48 (2025-09-30); 1.9x the same period a year earlier
4 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 142.3M vs usual 91.6M (2025-09-30); 1.5x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 121 vs usual 44.50 (2025-06-30); 1.0x the same period a year earlier
14 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MMM (2025-06-30)
16 May 20258-K and other filingsDirector or officer change
13 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.1M vs usual 4.2M (2025-03-31); 2.2x the same period a year earlier
18 Apr 2025Lobbying filingnew lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
17 Apr 20258-K and other filingsDirector or officer change
20 Feb 20258-K and other filingsDirector or officer change
20 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Nov 20248-K and other filingsA major agreement ended
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 118 vs usual 33.50 (2024-06-30); 5.1x the same period a year earlier
13 May 20248-K and other filingsDirector or officer change
13 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Feb 20248-K and other filingsA major agreement ended
11 May 20238-K and other filingsDirector or officer change
11 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 65.2M vs usual 44.5M (2022-06-30); 1.4x the same period a year earlier
23 May 20228-K and other filingsDirector or officer change
13 May 20228-K and other filingsDirector or officer change
22 Feb 2022Sharp changeQuarterly revenue change: quarterly revenue change, 56.1M vs usual 43.1M (2021-12-31); 1.4x the same period a year earlier
17 Feb 20228-K and other filingsDirector or officer change
17 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$2.7M published
Month from 1 Jan 2022: -$821K published
Month from 1 Mar 2022: -$2.2M published
Month from 1 May 2022: -$46K published
Month from 1 Jul 2022: -$2.2M published
Month from 1 Aug 2022: -$6.0M published
Month from 1 Nov 2022: $966K published
Month from 1 Jan 2023: -$680K published
Month from 1 May 2023: -$487K published
Month from 1 Jun 2023: -$344K published
Month from 1 Jul 2023: -$15K published
Month from 1 Nov 2023: -$2.7M published
Month from 1 Dec 2023: -$1.2M published
Month from 1 Jan 2024: -$4.4M published
Month from 1 May 2024: -$24.4M published
Month from 1 Jun 2024: -$4.3M published
Month from 1 Aug 2024: -$7.1M published
Month from 1 Sep 2024: -$18.4M published
Month from 1 Dec 2024: -$3.7M published
Month from 1 Jan 2025: -$9.1M published
Month from 1 Feb 2025: -$40.0M published
Month from 1 Mar 2025: -$4.0M published
Month from 1 Apr 2025: -$982K published
Month from 1 May 2025: -$7.1M published
Month from 1 Jun 2025: -$46.3M published
Month from 1 Jul 2025: -$13.1M published
Month from 1 Aug 2025: -$9.6M published
Month from 1 Sep 2025: -$43.0M published
Month from 1 Nov 2025: -$34.4M published
Month from 1 Dec 2025: -$9.9M published
Month from 1 Jan 2026: -$29.4M published
Month from 1 Feb 2026: -$9.8M published
Month from 1 Mar 2026: -$3.1M published
Month from 1 Apr 2026: -$20.7M published
Month from 1 May 2026: -$11.9M published
Month from 1 Jun 2026: -$4.9M published
Month from 1 Jul 2026: -$3.7M published
Month from 1 Aug 2026: -$36.1M published
Month from 1 Sep 2026: -$3.1M published
Month from 1 Nov 2026: -$14.7M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 3 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 5 published
Quarter from 1 Jul 2023: 4 published
Quarter from 1 Oct 2023: 3 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Jul 2024: 3 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 4 published
Quarter from 1 Jul 2025: 10 published
Quarter from 1 Oct 2025: 6 published
Quarter from 1 Jan 2026: 3 published
Quarter from 1 Apr 2026: 6 published
Quarter from 1 Jul 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $56.1M, +36% on a year earlier; public on 18 Feb 2022
Quarter ended 31 Mar 2022: $53.1M, +32% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $65.2M, +44% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $67.7M, +45% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $59.3M, +5.7% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $65.2M, +23% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $77.2M, +18% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $79.1M, +17% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $83.7M, +41% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $75.5M, +16% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $90.3M, +17% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $93.4M, +18% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $104.4M, +25% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $92.8M, +23% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $107.4M, +19% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $142.3M, +52% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $263.8M, +153% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $306.0M, +230% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $425.5M, +296% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $524.4M, +268% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $1.1M, +22% on a year earlier; public on 18 Feb 2022
Quarter ended 31 Mar 2022: $1.7M, +44% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $2.9M, -17% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $582K, -61% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $4.7M, +311% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $3.4M, +100% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $4.9M, +68% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $2.9M, +390% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $2.2M, -54% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $4.7M, +38% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $6.8M, +39% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3.7M, +29% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $6.8M, +215% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $10.1M, +115% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $3.5M, -49% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.4M, -34% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $16.6M, +145% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $3.5M, -65% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $6.3M, +80% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $5.6M, +133% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 194; public on 14 Feb 2022
31 Mar 2022 report: 210; public on 16 May 2022
30 Jun 2022 report: 200; public on 15 Aug 2022
30 Sep 2022 report: 218; public on 14 Nov 2022
31 Dec 2022 report: 208; public on 14 Feb 2023
31 Mar 2023 report: 215; public on 15 May 2023
30 Jun 2023 report: 208; public on 14 Aug 2023
30 Sep 2023 report: 234; public on 14 Nov 2023
31 Dec 2023 report: 258; public on 14 Feb 2024
31 Mar 2024 report: 279; public on 15 May 2024
30 Jun 2024 report: 363; public on 14 Aug 2024
30 Sep 2024 report: 396; public on 14 Nov 2024
31 Dec 2024 report: 420; public on 14 Feb 2025
31 Mar 2025 report: 425; public on 15 May 2025
30 Jun 2025 report: 491; public on 14 Aug 2025
30 Sep 2025 report: 536; public on 14 Nov 2025
31 Dec 2025 report: 648; public on 17 Feb 2026
31 Mar 2026 report: 657; public on 15 May 2026
30 Jun 2026 report: 652; public on 14 Aug 2026
30 Sep 2026 report: 695; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2022: $0 published
Month from 1 Jul 2023: $54K published
Month from 1 Sep 2023: $0 published
Month from 1 Jan 2024: -$27K published
Month from 1 Feb 2025: $10K published
Month from 1 Mar 2025: $71K published
Month from 1 Apr 2025: $10K published
Month from 1 May 2025: -$148K published
Month from 1 Jun 2025: $20K published
Month from 1 Oct 2025: -$61K published
Month from 1 Jun 2026: $31K published
Lobbying spend
Quarter from 1 Jul 2025: $10K published
Quarter from 1 Oct 2025: $10K published
Quarter from 1 Jan 2026: $10K published
Quarter from 1 Apr 2026: $10K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $60K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $524.4M for the quarter ended 30 Sep 2026, 3.7× the same quarter last year. Two or more unrelated kinds of activity agreed on 11 Aug 2026.
  • Quarterly revenue change: reported revenue of $524.4M for the quarter ended 30 Sep 2026, 3.7× the same quarter last year Public on 3 Nov 2026.
  • Short interest spike: had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $147.4M in the last 12 months (the 12 months before: -$211.2M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $17.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Nov 2026Orlov S Nicole SchaefferChief People Strategy OfficerSellplanned in advance (10b5-1); after exercising options101,100$145.26$14.7MForm 4
11 Sep 2026David R BrennanDirectorSell25,000$124.00$3.1MForm 4
19 Aug 2026Melvin Sharoky MdDirectorSell5,000$127.53$638KForm 4
12 Aug 2026Roger AdsettChief Operating OfficerSellafter exercising options239,850$133.27$32.0MForm 4
7 Aug 2026Martina Flammer M.d.Chief Medical OfficerSellplanned in advance (10b5-1); after exercising options27,173$128.61$3.5MForm 4
24 Jul 2026William LewisChair and CEOSellplanned in advance (10b5-1); after exercising options10,700$106.06$1.1MForm 4
10 Jul 2026William LewisChair and CEOSellplanned in advance (10b5-1); after exercising options10,699$117.40$1.3MForm 4
8 Jul 2026Martina Flammer M.d.Chief Medical OfficerSellplanned in advance (10b5-1); after exercising options12,302$109.98$1.4MForm 4

695 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 118 opened a position, 86 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.15.9M7.25%$1.8B+101K+0.6%
FMR LLC (Fidelity)15.5M7.07%$1.8B-625K-3.9%
Vanguard Portfolio Management LLC10.5M4.80%$1.2B+122K+1.2%
Vanguard Capital Management LLC9.8M4.48%$1.1B+43K+0.4%
Capital International Investors9.4M4.26%$1.1B+1.1M+14%
Baker Bros. Advisors LP8.8M4.01%$1.0BNo change
JPMorgan Chase & Co8.2M3.76%$953.2M-2.2M-21%
Orbis Allan Gray Ltd6.7M3.07%$768.6M+657K+11%
Ameriprise Financial Inc6.3M2.85%$713.5M+71K+1.2%
State Street Corp6.2M2.81%$703.4M+110K+1.8%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 27 Aug 2019. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
27 Aug 2019Department of Health and Human ServicesFood and Drug Administration$1.7MDEVELOPMENT OF A NOVEL PRO TOOL FOR USE IN CLINICAL TRIALS TO MEASURE SYMPTOMS IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS WITH AND WITHOUT NON-TUBERCULOUS MYCOBACTERIAL LUNG INFECTIONGrantUSAspending

Company events

All 37 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Oct 2026Director or officer change8-K
5 Oct 2026Director or officer change8-K
19 Feb 2026Director or officer change8-K
16 May 2025Director or officer changeSame filing: shareholder vote results8-K
17 Apr 2025Director or officer change8-K
20 Feb 2025Director or officer change8-K
19 Nov 2024A major agreement ended8-K
31 Oct 2024Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $60K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jun 2026NewLMH Strategic Solutionsfor Insmed IncorporatedMFN Issues.TradeFiling
18 Mar 2025NewJeffrey J. Kimbell & Associates, Inc.for Insmed, Inc.Issues related to the pharmaceutical industry and Medicare drug reimbursementHealth issues, Medicare/MedicaidFiling
31 Mar 2019EndedBaker & Hostetler LLPfor Insmed IncorporatedRegulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.Health issuesFiling
1 Jan 2018NewBaker & Hostetler LLPfor Insmed IncorporatedPolicy issues relating to federal healthcare regulatory and reimbursement matters.Health issuesFiling
31 Jan 2009EndedRubicon Advisors, LLCfor Insmed IncorporatedGeneric Biologics S. 1695PharmacyFiling
14 Feb 2008NewRubicon Advisors, LLCfor Insmed IncorporatedPharmaceutical IssuesPharmacyFiling
1 Feb 2007NewThe Washington Groupfor Insmed IncHealth issuesFiling
31 Dec 2006EndedThe Washington Groupfor Insmed IncBioShield - provisions related to bioterrorism response.Health issuesFiling

The 5 newest of 462 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

11 Aug 2026confirmed

Confirmed across sources Filings + Financials and Lobbying

Insmed (INSM): lobbying on a new issue, while it reported revenue of $425.5M for the quarter ended 30 Jun 2026, 4.0× the same quarter last year. Two unrelated kinds of activity within 22 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Jul 2026
  • Financials: Quarterly revenue change, became public on 11 Aug 2026
2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M2026-06-30: $425.5M
The quarter ended 30 Jun 2026 against the 8 quarters before it. this quarterearliernormal: $105.9M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 20 Jul 2026

Insmed lobbying on a new issue.

New
['TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4555090

Financials: Quarterly revenue change became public on 11 Aug 2026

Insmed reported revenue of $425.5M for the quarter ended 30 Jun 2026, 4.0× the same quarter last year.

This period
$425.5M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$105.9M
Typical spread (median absolute deviation)
$14.3M
How far from its usual level
+15.0
Same quarter last year
$107.4M
History used
5,844 days
2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M2026-06-30: $425.5M
the quarter ended 30 Jun 20268 earlier quartersnormal: $105.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

2 Jun 2026confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Insmed (INSM): reported revenue of $306.0M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year, while it had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year. Two unrelated kinds of activity within 35 days.

  • Financials: Quarterly revenue change, became public on 12 May 2026
  • Short interest and volume: Short interest spike, became public on 28 May 2026
  • Short interest and volume: Short interest spike, became public on 10 Jun 2026
2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M
The quarter ended 31 Mar 2026 against the 8 quarters before it. this quarterearliernormal: $98.9M
See the evidence (3 changes)

Financials: Quarterly revenue change became public on 12 May 2026

Insmed reported revenue of $306.0M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year.

This period
$306.0M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$98.9M
Typical spread (median absolute deviation)
$8.5M
How far from its usual level
+16.4
Same quarter last year
$92.8M
History used
5,753 days
2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M
the quarter ended 31 Mar 20268 earlier quartersnormal: $98.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 28 May 2026

Insmed had 17.6M shares sold short in the 15 May 2026 report, 1.1× the same report last year.

This period
17.6M (the 15 May 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+4.6
Same report last year
16.5M
History used
3,059 days
2025-05-15: 16.5M2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M
the 15 May 2026 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2026

Insmed had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year.

This period
19.1M (the 29 May 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+5.6
Same report last year
17.5M
History used
3,073 days
2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M2026-05-29: 19.1M
the 29 May 2026 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

24 Feb 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Insmed (INSM): saw 160 13F filers open a new position in the quarter ended 31 Dec 2025, 3.5× the same quarter last year, while it reported revenue of $263.8M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
  • Financials: Quarterly capital spending jump, became public on 24 Feb 2026
  • Financials: Quarterly revenue change, became public on 24 Feb 2026
2023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 1172025-12-31: 160
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: 56.5
See the evidence (3 changes)

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

Insmed saw 160 13F filers open a new position in the quarter ended 31 Dec 2025, 3.5× the same quarter last year.

This period
160 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
56.5
Typical spread (median absolute deviation)
17
How far from its usual level
+4.1
Same quarter last year
46
History used
4,475 days
2023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 1172025-12-31: 160
the quarter ended 31 Dec 20258 earlier quartersnormal: 56.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly capital spending jump became public on 24 Feb 2026

Insmed spent $16.6M on capital projects in the quarter ended 31 Dec 2025, 2.4× the same quarter last year.

This period
$16.6M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$4.2M
Typical spread (median absolute deviation)
$1.9M
How far from its usual level
+4.4
Same quarter last year
$6.8M
History used
5,571 days
2023-12-31: $2.2M2024-03-31: $4.7M2024-06-30: $6.8M2024-09-30: $3.7M2024-12-31: $6.8M2025-03-31: $10.1M2025-06-30: $3.5M2025-09-30: $2.4M2025-12-31: $16.6M
the quarter ended 31 Dec 20258 earlier quartersnormal: $4.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Financials: Quarterly revenue change became public on 24 Feb 2026

Insmed reported revenue of $263.8M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

This period
$263.8M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$93.1M
Typical spread (median absolute deviation)
$10.4M
How far from its usual level
+11.1
Same quarter last year
$104.4M
History used
5,663 days
2023-12-31: $83.7M2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M
the quarter ended 31 Dec 20258 earlier quartersnormal: $93.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 3 Nov 2026Financials change

    reported revenue of $524.4M for the quarter ended 30 Sep 2026, 3.7× the same quarter last year.

    Same quarter last year: $142.3M; its normal quarter is $124.9M.

    See the evidence
    This period
    $524.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $124.9M
    Typical spread (median absolute deviation)
    $31.8M
    How far from its usual level
    +8.5
    Same quarter last year
    $142.3M
    History used
    5,936 days
    2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M2026-06-30: $425.5M2026-09-30: $524.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $124.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 20 Oct 2026Filings record

    Director or officer change

  3. 5 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 5 Oct 2026Filings record

    Director or officer change

  5. 11 Aug 2026several at once

    lobbying on a new issue, while it reported revenue of $425.5M for the quarter ended 30 Jun 2026, 4.0× the same quarter last year. Two unrelated kinds of activity within 22 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 20 Jul 2026

    Insmed lobbying on a new issue.

    New
    ['TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4555090

    Financials: Quarterly revenue change became public on 11 Aug 2026

    Insmed reported revenue of $425.5M for the quarter ended 30 Jun 2026, 4.0× the same quarter last year.

    This period
    $425.5M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $105.9M
    Typical spread (median absolute deviation)
    $14.3M
    How far from its usual level
    +15.0
    Same quarter last year
    $107.4M
    History used
    5,844 days
    2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M2026-06-30: $425.5M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $105.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  6. 11 Aug 2026Financials change

    reported revenue of $425.5M for the quarter ended 30 Jun 2026, 4.0× the same quarter last year.

    Same quarter last year: $107.4M; its normal quarter is $105.9M.

    See the evidence
    This period
    $425.5M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $105.9M
    Typical spread (median absolute deviation)
    $14.3M
    How far from its usual level
    +15.0
    Same quarter last year
    $107.4M
    History used
    5,844 days
    2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M2026-06-30: $425.5M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $105.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 20 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4555090
  8. 17 Jul 2026Lobbying record

    INSMED INCORPORATED: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jun 2026)

  9. 10 Jun 2026Short interest and volume change

    had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year.

    Same report last year: 17.5M; its normal report is 10.7M.

    See the evidence
    This period
    19.1M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +5.6
    Same report last year
    17.5M
    History used
    3,073 days
    2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M2026-05-29: 19.1M
    the 29 May 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 2 Jun 2026several at once

    reported revenue of $306.0M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year, while it had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year. Two unrelated kinds of activity within 35 days.

    See the evidence (3 changes)

    Financials: Quarterly revenue change became public on 12 May 2026

    Insmed reported revenue of $306.0M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year.

    This period
    $306.0M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $98.9M
    Typical spread (median absolute deviation)
    $8.5M
    How far from its usual level
    +16.4
    Same quarter last year
    $92.8M
    History used
    5,753 days
    2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $98.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 28 May 2026

    Insmed had 17.6M shares sold short in the 15 May 2026 report, 1.1× the same report last year.

    This period
    17.6M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.6
    Same report last year
    16.5M
    History used
    3,059 days
    2025-05-15: 16.5M2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M
    the 15 May 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2026

    Insmed had 19.1M shares sold short in the 29 May 2026 report, 1.1× the same report last year.

    This period
    19.1M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +5.6
    Same report last year
    17.5M
    History used
    3,073 days
    2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M2026-05-29: 19.1M
    the 29 May 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  11. 28 May 2026Short interest and volume change

    had 17.6M shares sold short in the 15 May 2026 report, 1.1× the same report last year.

    Same report last year: 16.5M; its normal report is 10.7M.

    See the evidence
    This period
    17.6M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.6
    Same report last year
    16.5M
    History used
    3,059 days
    2025-05-15: 16.5M2025-05-30: 17.5M2025-06-13: 11.7M2025-06-30: 9.8M2025-07-15: 9.7M2025-07-31: 9.5M2025-08-15: 10.5M2025-08-29: 10.6M2025-09-15: 10.6M2025-09-30: 10.7M2025-10-15: 9.5M2025-10-31: 8.0M2025-11-14: 8.9M2025-11-28: 9.9M2025-12-15: 8.9M2025-12-31: 11.0M2026-01-15: 11.9M2026-01-30: 11.7M2026-02-13: 11.5M2026-02-27: 11.3M2026-03-13: 10.0M2026-03-31: 13.8M2026-04-15: 13.9M2026-04-30: 14.7M2026-05-15: 17.6M
    the 15 May 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 12 May 2026Financials change

    reported revenue of $306.0M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year.

    Same quarter last year: $92.8M; its normal quarter is $98.9M.

    See the evidence
    This period
    $306.0M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $98.9M
    Typical spread (median absolute deviation)
    $8.5M
    How far from its usual level
    +16.4
    Same quarter last year
    $92.8M
    History used
    5,753 days
    2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M2026-03-31: $306.0M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $98.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 24 Feb 2026several at once

    saw 160 13F filers open a new position in the quarter ended 31 Dec 2025, 3.5× the same quarter last year, while it reported revenue of $263.8M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (3 changes)

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    Insmed saw 160 13F filers open a new position in the quarter ended 31 Dec 2025, 3.5× the same quarter last year.

    This period
    160 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    56.5
    Typical spread (median absolute deviation)
    17
    How far from its usual level
    +4.1
    Same quarter last year
    46
    History used
    4,475 days
    2023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 1172025-12-31: 160
    the quarter ended 31 Dec 20258 earlier quartersnormal: 56.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Financials: Quarterly capital spending jump became public on 24 Feb 2026

    Insmed spent $16.6M on capital projects in the quarter ended 31 Dec 2025, 2.4× the same quarter last year.

    This period
    $16.6M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $4.2M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +4.4
    Same quarter last year
    $6.8M
    History used
    5,571 days
    2023-12-31: $2.2M2024-03-31: $4.7M2024-06-30: $6.8M2024-09-30: $3.7M2024-12-31: $6.8M2025-03-31: $10.1M2025-06-30: $3.5M2025-09-30: $2.4M2025-12-31: $16.6M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $4.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Financials: Quarterly revenue change became public on 24 Feb 2026

    Insmed reported revenue of $263.8M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

    This period
    $263.8M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $93.1M
    Typical spread (median absolute deviation)
    $10.4M
    How far from its usual level
    +11.1
    Same quarter last year
    $104.4M
    History used
    5,663 days
    2023-12-31: $83.7M2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $93.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  14. 24 Feb 2026Financials change

    reported revenue of $263.8M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

    Same quarter last year: $104.4M; its normal quarter is $93.1M.

    See the evidence
    This period
    $263.8M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $93.1M
    Typical spread (median absolute deviation)
    $10.4M
    How far from its usual level
    +11.1
    Same quarter last year
    $104.4M
    History used
    5,663 days
    2023-12-31: $83.7M2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M2025-12-31: $263.8M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $93.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 24 Feb 2026Financials change

    spent $16.6M on capital projects in the quarter ended 31 Dec 2025, 2.4× the same quarter last year.

    Same quarter last year: $6.8M; its normal quarter is $4.2M.

    See the evidence
    This period
    $16.6M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $4.2M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +4.4
    Same quarter last year
    $6.8M
    History used
    5,571 days
    2023-12-31: $2.2M2024-03-31: $4.7M2024-06-30: $6.8M2024-09-30: $3.7M2024-12-31: $6.8M2025-03-31: $10.1M2025-06-30: $3.5M2025-09-30: $2.4M2025-12-31: $16.6M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $4.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 19 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 19 Feb 2026Filings record

    Director or officer change

  18. 17 Feb 2026Institutional holdings change

    saw 160 13F filers open a new position in the quarter ended 31 Dec 2025, 3.5× the same quarter last year.

    Same quarter last year: 46; its normal quarter is 56.5.

    See the evidence
    This period
    160 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    56.5
    Typical spread (median absolute deviation)
    17
    How far from its usual level
    +4.1
    Same quarter last year
    46
    History used
    4,475 days
    2023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 1172025-12-31: 160
    the quarter ended 31 Dec 20258 earlier quartersnormal: 56.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  19. 18 Nov 2025several at once

    reported revenue of $142.3M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year, while it saw 117 13F filers open a new position in the quarter ended 30 Sep 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 4 Nov 2025

    Insmed reported revenue of $142.3M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    This period
    $142.3M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $91.6M
    Typical spread (median absolute deviation)
    $10.2M
    How far from its usual level
    +3.4
    Same quarter last year
    $93.4M
    History used
    5,571 days
    2023-09-30: $79.1M2023-12-31: $83.7M2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $91.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    Insmed saw 117 13F filers open a new position in the quarter ended 30 Sep 2025, 1.9× the same quarter last year.

    This period
    117 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    48
    Typical spread (median absolute deviation)
    8.5
    How far from its usual level
    +5.5
    Same quarter last year
    63
    History used
    4,383 days
    2023-09-30: 432023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 117
    the quarter ended 30 Sep 20258 earlier quartersnormal: 48

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  20. 14 Nov 2025Institutional holdings change

    saw 117 13F filers open a new position in the quarter ended 30 Sep 2025, 1.9× the same quarter last year.

    Same quarter last year: 63; its normal quarter is 48.

    See the evidence
    This period
    117 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    48
    Typical spread (median absolute deviation)
    8.5
    How far from its usual level
    +5.5
    Same quarter last year
    63
    History used
    4,383 days
    2023-09-30: 432023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 1212025-09-30: 117
    the quarter ended 30 Sep 20258 earlier quartersnormal: 48

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 4 Nov 2025Financials change

    reported revenue of $142.3M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    Same quarter last year: $93.4M; its normal quarter is $91.6M.

    See the evidence
    This period
    $142.3M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $91.6M
    Typical spread (median absolute deviation)
    $10.2M
    How far from its usual level
    +3.4
    Same quarter last year
    $93.4M
    History used
    5,571 days
    2023-09-30: $79.1M2023-12-31: $83.7M2024-03-31: $75.5M2024-06-30: $90.3M2024-09-30: $93.4M2024-12-31: $104.4M2025-03-31: $92.8M2025-06-30: $107.4M2025-09-30: $142.3M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $91.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 14 Aug 2025Institutional holdings change

    saw 121 13F filers open a new position in the quarter ended 30 Jun 2025, 1.0× the same quarter last year.

    Same quarter last year: 118; its normal quarter is 44.5.

    See the evidence
    This period
    121 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    44.5
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +7.9
    Same quarter last year
    118
    History used
    4,291 days
    2023-06-30: 232023-09-30: 432023-12-31: 372024-03-31: 422024-06-30: 1182024-09-30: 632024-12-31: 462025-03-31: 502025-06-30: 121
    the quarter ended 30 Jun 20258 earlier quartersnormal: 44.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 14 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4824242
  24. 23 May 2025Insiders record

    Desjardins Clarissa (director) bought 3,025 shares of INSM ($201,694) (dated 22 May 2025)

  25. 16 May 2025Filings record

    Director or officer change

  26. 13 May 2025Financials change

    spent $10.1M on capital projects in the quarter ended 31 Mar 2025, 2.2× the same quarter last year.

    Same quarter last year: $4.7M; its normal quarter is $4.2M.

    See the evidence
    This period
    $10.1M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $4.2M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +3.8
    Same quarter last year
    $4.7M
    History used
    5,296 days
    2023-03-31: $3.4M2023-06-30: $4.9M2023-09-30: $2.9M2023-12-31: $2.2M2024-03-31: $4.7M2024-06-30: $6.8M2024-09-30: $3.7M2024-12-31: $6.8M2025-03-31: $10.1M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $4.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 18 Apr 2025Lobbying record

    INSMED, INC.: new lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 18 Mar 2025)

  28. 17 Apr 2025Filings record

    Director or officer change

  29. 20 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 20 Feb 2025Filings record

    Director or officer change

  31. 19 Nov 2024Filings record

    A major agreement ended

  32. 14 Aug 2024Institutional holdings change

    saw 118 13F filers open a new position in the quarter ended 30 Jun 2024, 5.1× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 33.5.

    See the evidence
    This period
    118 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    33.5
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +7.6
    Same quarter last year
    23
    History used
    3,926 days
    2022-06-30: 182022-09-30: 402022-12-31: 292023-03-31: 302023-06-30: 232023-09-30: 432023-12-31: 372024-03-31: 422024-06-30: 118
    the quarter ended 30 Jun 20248 earlier quartersnormal: 33.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 13 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 13 May 2024Filings record

    Director or officer change

  35. 22 Feb 2024Filings record

    A major agreement ended

  36. 18 May 2023Insiders record

    SHAROKY MELVIN MD (director) bought 20,000 shares of INSM ($385,800) (dated 17 May 2023)

  37. 11 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 11 May 2023Filings record

    Director or officer change

  39. 3 Nov 2022Insiders record

    SHAROKY MELVIN MD (director) bought 30,000 shares of INSM ($527,600) (dated 2 Nov 2022)

  40. 3 Nov 2022Insiders record

    LEE LEO (director) bought 45,000 shares of INSM ($796,050) (dated 2 Nov 2022)

Showing the newest 40 of 95 entries; narrow the window or the kind of data to see older ones.

Not listed: 390 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001104506
Ticker
INSM
Domain
insmed.com
Employer name
INSMED, INC. (1 unverified)
Hq location
NJ|BRIDGEWATER|08807 (1 unverified)
Lobbying client
insmed
Name
Celtrix Pharmaceuticals, Inc, Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany GmbH and 9 more
Uei
GLE1HZQ47JW6
  • DOL H-1B labor condition applications and PERM certifications231 data points1 Oct 2019 to 10 Aug 2026
  • Federal lobbying disclosures (LDA)8 records, 88 data points31 Dec 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)161 records25 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1056 data points31 Dec 2008 to 23 Oct 2026
  • SEC Form 4 insider transactions273 records, 600 data points3 Feb 2016 to 20 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 48 data points27 Aug 2019 to 10 Jun 2026